DermatologicalICD-10: L73.2Affects approximately 1-4% of the global population

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful lumps, abscesses, and tunnels (sinus tracts) that form under the skin in areas where skin rubs together. It typically affects the armpits, groin, buttocks, and under the breasts, and is often misdiagnosed as boils or simple skin infections. HS is a progressive disease that can significantly impact quality of life, and early diagnosis and treatment are essential to prevent scarring and complications.

Last updated November 10, 2026

Understanding Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle that produces painful, deep nodules, abscesses and draining tunnels in the armpits, groin, buttocks and under the breasts. It is not an infection and it is not caused by poor hygiene, although it is routinely mistaken for recurrent boils: the average delay from first symptoms to a correct diagnosis is 7 to 10 years in published series. Population studies put prevalence at roughly 1 percent of adults, while US insurance-claims data come closer to 0.1 percent because so many cases are never coded. Women are affected about three times as often as men, onset is usually between the late teens and 40, and Black Americans carry the highest prevalence. About a third of people have an affected relative. Two exposures stand out above everything else: 70 to 90 percent of people with HS smoke or have smoked, and most are overweight or obese, with severity tracking body weight closely.

HS begins with a blocked hair follicle, not a sweat gland as was once thought. The follicle plugs with keratin, dilates, and eventually ruptures into the surrounding dermis, spilling keratin and bacteria that trigger an intense immune response driven by TNF-alpha, interleukin-1 and interleukin-17. Repeated rupture and healing create the tunnels (sinus tracts) and rope-like scars that define advanced disease. Severity is described with Hurley staging: stage I is abscesses without tunnels or scarring, stage II is recurrent abscesses with tunnels and scars in separate areas, and stage III is diffuse involvement with multiple interconnected tunnels across a whole region. Roughly two-thirds of people stay in stage I, but a tunnel, once formed, does not disappear with medication, which is why early treatment matters so much. Pain, drainage and odor drive high rates of depression, and HS travels with metabolic syndrome, inflammatory bowel disease and polycystic ovary syndrome.

The 2019 North American clinical management guidelines set out a tiered approach. Stage I is managed with daily antiseptic washes (chlorhexidine 4 percent or benzoyl peroxide), topical clindamycin, intralesional steroid injections into painful nodules, and oral tetracyclines for flares. Moderate disease gets a 10-week course of clindamycin plus rifampin, hormonal therapy (spironolactone or metformin) where appropriate, and laser hair removal. For moderate-to-severe disease adalimumab was the first approved biologic: in the PIONEER I and II trials (633 patients) 42 and 59 percent of those treated reached a clinical response at 12 weeks versus 26 and 28 percent on placebo. Secukinumab (SUNSHINE and SUNRISE, 1,084 patients, published 2023) and bimekizumab (BE HEARD I and II, approved for HS in 2024) block interleukin-17 and give similar or somewhat higher response rates, which matters when adalimumab stops working. Tunnels and stage III regions are treated surgically, by deroofing or wide excision, because no drug removes an established tract.

There is no natural treatment for HS with Strong or Moderate evidence, and no supplement shrinks a tunnel. The two biggest levers are behaviors, not products. In a Danish study of 383 people who had bariatric surgery, those with HS who lost more than 15 percent of body weight had a 35 percent chance of complete remission and most of the rest improved; smoking cessation is linked with milder disease in observational studies, although no randomized trial exists. Oral zinc gluconate has the most clinical data of any supplement: a handful of open-label and retrospective studies, the largest with 90 patients, report fewer flares, mostly in Hurley stage I and II disease. A small pilot found that correcting low vitamin D reduced nodule counts. Dairy-free, low-glycemic and brewer's-yeast-free diets each rest on a single uncontrolled case series and should be treated as personal experiments, not evidence. Turmeric, tea tree oil, probiotics and 'anti-inflammatory' protocols have no HS trials at all.

The most common mistake is treating each flare as a boil: a course of antibiotics from urgent care, a lancing, and then nothing until the next one. Incision and drainage relieves pressure for a few days but the lesion recurs in almost every case, and repeated short antibiotic courses breed resistance without changing the disease. The better approach is to get the diagnosis named, usually by a dermatologist, ask for a Hurley stage, and start maintenance treatment between flares, which for most people begins with antiseptic washes, topical clindamycin and a long-term plan on smoking and weight. The second mistake is waiting too long for biologics: people who reach stage III have fixed scarring that no injection reverses, so a conversation about adalimumab or an interleukin-17 inhibitor belongs at the point where antibiotics stop working, not years later.

At a Glance

Common symptoms
Painful, deep-seated nodules or lumps under the skin, Recurrent abscesses that drain foul-smelling pus, Blackheads, often appearing in pairs (double-barreled comedones)
Main treatments
Topical or oral antibiotics (clindamycin, doxycycline, rifampin) for inflammatory control, Biologic therapy (adalimumab/Humira, secukinumab) for moderate to severe disease, Intralesional corticosteroid injections for acute flares
Category
Dermatological · Affects approximately 1-4% of the global population
See a doctor if
You develop recurrent painful lumps or abscesses in the armpits, groin, or other skin folds

Symptoms

Painful, deep-seated nodules or lumps under the skin
Recurrent abscesses that drain foul-smelling pus
Blackheads, often appearing in pairs (double-barreled comedones)
Tunnels (sinus tracts) connecting lumps under the skin
Scarring and skin thickening in affected areas
Flare-ups followed by periods of partial improvement
Pain and difficulty moving when lesions occur in skin folds

Causes

  • Occlusion and inflammation of hair follicles (follicular plugging)
  • Dysregulated immune response leading to chronic inflammation
  • Genetic predisposition (family history present in about one-third of patients)
  • Hormonal factors (HS often begins after puberty)
  • Bacterial colonization of lesions as a secondary phenomenon

Risk Factors

  • Family history of hidradenitis suppurativa
  • Obesity (friction and sweating in skin folds worsen the condition)
  • Female sex (women are affected approximately three times more than men)
  • Smoking (strongly associated with disease severity)
  • Age between 20 and 40 years at onset
  • African American descent (higher prevalence)

Diagnosis

  • Clinical diagnosis based on characteristic lesion appearance, location, and recurrence pattern
  • No specific blood test or imaging is required for diagnosis
  • Skin biopsy in atypical cases to rule out other conditions
  • Assessment of disease severity using the Hurley staging system (Stage I-III)

Treatment

  • Topical or oral antibiotics (clindamycin, doxycycline, rifampin) for inflammatory control
  • Biologic therapy (adalimumab/Humira, secukinumab) for moderate to severe disease
  • Intralesional corticosteroid injections for acute flares
  • Surgical excision or deroofing of chronic sinus tracts and abscesses
  • Hormonal therapy (spironolactone, oral contraceptives) for female patients
  • Laser hair removal in affected areas to reduce follicular plugging
  • Pain management and wound care

Natural remedies for hidradenitis suppurativa: what the evidence says

Ranked by the strength of human evidence for hidradenitis suppurativa specifically. These sit alongside medical care, not in place of it.

  1. Zinc

    Preliminary evidence

    In the first open study, 22 people with Hurley stage I and II disease took 90 mg of zinc (as gluconate) daily and 8 had complete and 14 partial remission, with relapse when the dose was reduced. A 2020 retrospective study of 90 patients with mild-to-moderate HS found 90 mg zinc plus 30 mg nicotinamide daily for 24 weeks reduced flares about as well as topical clindamycin. None of this is placebo-controlled, so the evidence stays preliminary.

    Studied dose
    90 mg elemental zinc as zinc gluconate daily in the studies, which is above the 40 mg tolerable upper limit and needs clinician supervision; 2 mg copper is often added.
    Cautions
    Doses this high cause nausea and, over months, copper deficiency with anemia and nerve damage, so take only with periodic zinc and copper checks. Zinc binds tetracyclines and quinolones; separate by 2 to 4 hours.
  2. Vitamin D

    Preliminary evidence

    Low vitamin D is common in HS and correlates with lesion count. In a French pilot study, 22 people with HS and low vitamin D were given replacement for 6 months and 14 (79 percent) had fewer nodules, with the biggest drop in those whose blood levels rose the most. There is no placebo-controlled trial, so this is a reason to check and correct a deficiency rather than a treatment in itself.

    Studied dose
    Have a vitamin D level checked; typical repletion is 1,000 to 4,000 IU vitamin D3 daily, adjusted to the result.
    Cautions
    Doses above 4,000 IU daily without monitoring can raise blood calcium; use care with thiazide diuretics, digoxin and in sarcoidosis.

What matters day to day

  • Stop smoking, with help: 70 to 90 percent of people with HS smoke, nicotine drives follicular plugging and inflammation, and ex-smokers have milder disease than current smokers, so this is the first conversation worth having.
  • Aim for a 10 to 15 percent weight loss if you are overweight: in the Danish bariatric series, more than 15 percent loss led to remission in 35 percent and improvement in most, and weight tracks Hurley stage more tightly than any other modifiable factor.
  • Wash affected areas daily with a chlorhexidine 4 percent or benzoyl peroxide 10 percent wash, left on for a minute before rinsing: recommended in the North American guidelines to lower bacterial load and reduce flares.
  • Stop shaving and waxing flare-prone skin and ask about laser hair removal: Nd:YAG laser reduced lesion counts by about 65 percent after three monthly sessions in a randomized split-body trial.
  • Choose loose cotton or moisture-wicking clothing and avoid tight waistbands and underwires: friction and sweating in skin folds trigger follicular rupture, and most flares start where a seam rubs.
  • Screen for the company HS keeps: ask your clinician for an A1c, lipid panel and blood pressure check, since metabolic syndrome is about twice as common in HS, and for a depression screen, because up to a quarter of people with HS are affected.

Prevention

  • Maintain a healthy weight to reduce friction in skin folds
  • Quit smoking, which is strongly linked to disease activity
  • Wear loose-fitting, breathable clothing
  • Use gentle, fragrance-free cleansers on affected areas
  • Avoid shaving in areas prone to flares

When to See a Doctor

  • You develop recurrent painful lumps or abscesses in the armpits, groin, or other skin folds
  • Previous treatments for 'boils' have not prevented recurrence
  • The condition is worsening with new tunnels, drainage, or spreading lesions

Frequently Asked Questions

References

  1. Alikhan A, Sayed C, Alavi A, et al.. North American clinical management guidelines for hidradenitis suppurativa: Part I and Part II. Journal of the American Academy of Dermatology (2019)
  2. Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa (PIONEER I and II). New England Journal of Medicine (2016)
  3. Kimball AB, Jemec GBE, Alavi A, et al.. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): two randomised, placebo-controlled phase 3 trials. Lancet (2023)
  4. Kimball AB, Jemec GBE, Sayed CJ, et al.. Bimekizumab in moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two randomised, placebo-controlled phase 3 trials. Lancet (2024)
  5. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatology (2017)
  6. Kromann CB, Ibler KS, Kristiansen VB, Jemec GBE. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Dermato-Venereologica (2014)
  7. Brocard A, Knol AC, Khammari A, Dreno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology (2007)
  8. Molinelli E, Brisigotti V, Campanati A, et al.. Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: a controlled retrospective clinical study. Journal of the American Academy of Dermatology (2020)
  9. Guillet A, Brocard A, Bach Ngohou K, et al.. Verneuil's disease, innate immunity and vitamin D: a pilot study. Journal of the European Academy of Dermatology and Venereology (2015)
  10. National Institutes of Health Office of Dietary Supplements. Zinc: Fact Sheet for Health Professionals (2022)View source

Related Conditions

Evidence-graded guides

Have questions about Hidradenitis Suppurativa?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.